Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc.) on May 13, 2021. The filing serves to announce the results of operations for the first quarter ended March 31, 2021. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol VIRI.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Item 2.02 states that the detailed results of operations are contained in a press release included as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K document.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document acts solely as a notification that Q1 2021 results have been issued.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within its text. It explicitly notes that the information furnished pursuant to Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc. (VIRI), not Dogwood Therapeutics.
- Review Exhibit 99.1 (the Press Release dated May 13, 2021) to obtain actual financial figures for Q1 2021.
- Confirm the reporting period covers the quarter ended March 31, 2021.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.